Anteris raises $320M, Q1 cash burn $28.7M; PARADIGM trial enrols in US

Anteris Technologies Global Corp.

2026-Q1 EPS reported -$0.28 vs consensus -$0.16 ▼ miss (-78.8%)

Net operating cash outflows of $28.7M for Q1 2026, funding PARADIGM Trial and manufacturing scale-up.
R&D expenses $17.5M, driven by clinical trial costs, manufacturing process validation, and headcount expansion.
Completed $320M capital raises in January 2026 to support PARADIGM Trial and global commercialization of DurAVR THV.
Post quarter-end, US patient enrollment in the PARADIGM Trial commenced; CMS coverage determination supports reimbursement.
Presented EMBARK Study and EFS data at CRT 2026 and Sydney Valves 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Anteris Technologies Global Corp. reported financial results for first quarter of 2026.

Period: first quarter of 2026
Result: reported results

Exact text from the filing

today reported financial results for the quarter ended 31 March 2026, and provided a corporate update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Anteris Technologies Global Corp. filing history →

Source: SEC EDGAR

accession 0001140361-26-020896

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.